Company news

Fate Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Fate Therapeutics to Present at Upcoming May Investor Conferences

May 5, 2022

Fate Therapeutics Reports First Quarter 2022 Financial Results and Highlights Operational Progress

May 3, 2022

Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2022 Financial Results

April 21, 2022

Fate Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Operational Progress

February 27, 2022

Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2021 Financial Results

February 15, 2022

Fate Therapeutics to Present at Upcoming February Investor Conferences

February 1, 2022

Fate Therapeutics Announces FDA Clearance for FT536, a First-in-class MICA/B-targeted CAR NK Cell Product Candidate for the Treatment of Solid Tumors

January 9, 2022

Fate Therapeutics Showcases Positive Interim Phase 1 Data from FT596 Off-the-shelf, iPSC-derived CAR NK Cell Program for Relapsed / Refractory B-cell Lymphoma at 2021 ASH Annual Meeting

December 12, 2021

Fate Therapeutics Highlights Positive Durability of Response Data from FT516 Phase 1 Study for B-cell Lymphoma and Announces FDA Regenerative Medicine Advanced Therapy Designation Granted to FT516 for Relapsed / Refractory DLBCL

December 12, 2021

Fate Therapeutics to Host Virtual Event at the 2021 ASH Annual Meeting

December 7, 2021

Fate Therapeutics Announces Abstract Highlighting FT538 and FT573 Programs Selected for Presentation at SITC 2021 Annual Meeting Press Conference

November 8, 2021

Fate Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Operational Progress

November 3, 2021

Fate Therapeutics Announces Eight Presentations at the 2021 ASH Annual Meeting

November 3, 2021

Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2021 Financial Results

October 24, 2021

Fate Therapeutics Announces Presentations at the Society for Immunotherapy of Cancer 2021 Annual Meeting

September 30, 2021

Fate Therapeutics Announces Publication of FT538 Preclinical Data Demonstrating Enhanced Serial Killing and Functional Persistence without Cytokine Support

September 14, 2021

Fate Therapeutics Announces Positive Interim Clinical Data from its FT596 and FT516 Off-the-shelf, iPSC-derived NK Cell Programs for B-cell Lymphoma

August 18, 2021

Fate Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Operational Progress

August 3, 2021

Fate Therapeutics Appoints Yuan Xu to its Board of Directors

August 3, 2021

Fate Therapeutics Announces Treatment of First Patient in Landmark Phase 1 Clinical Trial of FT819, the First-ever iPSC-derived CAR T-Cell Therapy

August 1, 2021

Fate Therapeutics to Host Virtual Event Highlighting Interim Phase 1 Clinical Data from its Off-the-Shelf, iPSC-derived NK Cell Franchise for B-cell Lymphoma

July 15, 2021

Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2021 Financial Results

July 14, 2021

Fate Therapeutics Appoints Mark Plavsic, DVM, PhD, RAC as Chief Technical Officer

June 14, 2021

Fate Therapeutics Highlights Positive Interim Data from its Phase 1 Study of FT516 in Combination with Rituximab for B-cell Lymphoma at 2021 ASCO Annual Meeting

June 3, 2021

Fate Therapeutics Announces Encouraging Interim Phase 1 Data for iPSC-derived NK Cell Programs in Relapsed / Refractory Acute Myeloid Leukemia

May 12, 2021

Fate Therapeutics Reports First Quarter 2021 Financial Results and Highlights Operational Progress

May 4, 2021

Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2021 Financial Results

April 28, 2021

Fate Therapeutics Announces Four Presentations at the 2021 ASGCT Annual Meeting

April 26, 2021

Fate Therapeutics Announces Retirement of Chief Scientific Officer after 12 Years of Service

March 24, 2021

Fate Therapeutics Reports Fourth Quarter 2020 Financial Results and Highlights Operational Progress

February 23, 2021

Fate Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference

February 21, 2021

Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2020 Financial Results

February 18, 2021

Fate Therapeutics Announces Completion of Public Offering of Common Stock and Pre-Funded Warrants, and Full Exercise of Underwriters’ Option to Purchase Additional Shares

January 7, 2021

Fate Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

January 4, 2021

Fate Therapeutics Announces Proposed Public Offering of $350 Million of Common Stock

January 3, 2021

Fate Therapeutics Presents Patient Case Study Demonstrating Clinical Activity of FT596 in Refractory Diffuse Large B-cell Lymphoma

December 5, 2020

Fate Therapeutics Reports Positive Interim Data from its Phase 1 Study of FT516 in Combination with Rituximab for B-cell Lymphoma

December 3, 2020

Fate Therapeutics to Host Virtual Event at the 2020 ASH Annual Meeting

November 29, 2020

Fate Therapeutics Announces Participation in Upcoming Investor Conferences

November 11, 2020

Fate Therapeutics Reports Third Quarter 2020 Financial Results and Highlights Operational Progress

November 4, 2020

Fate Therapeutics Announces Twelve Presentations at the 2020 ASH Annual Meeting

November 4, 2020

Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2020 Financial Results

November 1, 2020

Fate Therapeutics Announces Presentations at the 2020 Society for Immunotherapy of Cancer Annual Meeting

October 14, 2020

Fate Therapeutics to Present at Jefferies Cell Therapy Virtual Summit

September 29, 2020

Fate Therapeutics Announces September Investor Events

September 3, 2020

Fate Therapeutics Appoints Edward Dulac as Chief Financial Officer

August 18, 2020

Fate Therapeutics Reports Second Quarter 2020 Financial Results and Highlights Operational Progress

August 4, 2020

Fate Therapeutics to Present at the Wedbush PacGrow Healthcare Virtual Conference

August 3, 2020

Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2020 Financial Results

July 28, 2020

Fate Therapeutics Announces Exclusive License Agreement with Baylor College of Medicine for Rejection-resistant iPSC-derived Cellular Therapies

July 13, 2020

← Newer news releases · Older news releases →

Calls

The 5 newest of 17 calls. Every call is listed under its year.

Decks

The 5 newest of 19 decks. Every deck is listed under its year.